Table 2.

Treatment/laboratory variables, comorbidities, and pre-ESRD care, by vascular access at first dialysis and day 60 of ESRD: DMMS Wave 2 HD patientsa

ParameterAVF at First Dialysis and Day 60 of ESRDAVG at First Dialysis and Day 60 of ESRDCVC at First Dialysis, AVF at Day 60 of ESRDCVC at First Dialysis, AVG at Day 60 of ESRDCVC at First Dialysis and Day 60 of ESRDPb
Treatment/laboratory variables
    albumin (g/dl)3.7 ± 0.53.6 ± 0.63.6 ± 0.53.5 ± 0.63.4 ± 0.6<0.0001
    creatinine (mg/dl)8.6 ± 3.77.3 ± 2.68.7 ± 5.77.6 ± 3.37.7 ± 6.00.006
    phosphorus (mg/dl)5.7 ± 2.15.6 ± 1.85.6 ± 1.95.8 ± 3.85.6 ± 4.00.93
    hemoglobin (g/dl)11.2 ± 6.910.2 ± 2.910.8 ± 7.69.9 ± 2.610.1 ± 3.50.007
    taking EPO in first 60 db (%)94.695.995.795.896.30.94
    predialysis systolic BP (mmHg)151.7 ± 21.2151.8 ± 20.0154.9 ± 20.5151.1 ± 21.3148.9 ± 21.90.04
    body mass index25.8 ± 6.127.8 ± 12.826.1 ± 7.526.3 ± 9.324.3 ± 6.40.0008
    Kt/V1.2 ± 0.41.3 ± 0.41.1 ± 0.41.3 ± 0.41.2 ± 0.4<0.0001
Diabetic ESRD (%)34.053.735.443.239.1<0.0001
Comorbidities (%)
    coronary heart disease34.742.937.840.940.10.52
    congestive heart failure28.242.433.843.544.30.003
    cerebrovascular disease15.119.913.618.619.00.49
    peripheral vasculopathy17.925.015.422.823.30.14
    combined cardiovascularc56.972.361.266.769.50.009
    lung disease14.29.414.312.415.90.11
    cancer, excluding skin8.910.57.313.013.30.19
    HIV2.10.02.15.64.70.11
Pre-ESRD care (%)<0.0001
    early referral (≥4 mo pre-ESRD)82.169.762.051.551.2
    late referral (<4 mo pre-ESRD)17.930.338.048.548.8
  • a EPO, erythropoietin.

  • b Differences among vascular access categories using ANOVA to compare means and χ2 tests to compare proportions.

  • c One or more of the following: Coronary heart disease, congestive heart failure, cerebrovascular disease, peripheral vasculopathy, coronary artery disease, acute myocardial infarction, or cardiac arrest.